George,
I've done my amateurish best to read the papers on IGF-1 (many) and somatokine (one, plus some abstracts), particularly as they might apply to diabetes. And though somatokine has apparently succeeded in administering very high doses of IGF-1 complexed with BP3, in short studies, without the SEs of what had been thought of a really high doses of IGF-1 alone, they have really not proven anything about the specifics of its drug's usefullness in a reasonable commercial setting. As I look at what has to be done to tease out the MOA in the clinic, show also that the favorable insulin and glucose responses are durable beyond a couple weeks, and to prove no long term adverse consequences in the diabetic population, I see why they can not take it forward alone. I think they'll get little off-label use in T1 if GHIS is approved, but they might get some T2. Put another way, it is pretty clear to me now why the company's chances are reduced to one: GHIS, for which it is apparently a 'natural'.
Anyway I'm staying on the sidelines for a while longer. I could easily change my mind depending on what's reported at ADA. I truly hope the drug succeeds, it very well may. If so, huge upside.
BTW, even though bvf has so many shares it is an INSM insider, it is still a small position in the fund.
Thought I owed it to you to close the loop.
Wilder |
